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Background. Although speciﬁc phobia is highly prevalent, associated with impairment, and an important risk factor for
the development of other mental disorders, cross-national epidemiological data are scarce, especially from low- and mid-
dle-income countries. This paper presents epidemiological data from 22 low-, lower-middle-, upper-middle- and high-
income countries.
Method. Data came from 25 representative population-based surveys conducted in 22 countries (2001–2011) as part of
the World Health Organization World Mental Health Surveys initiative (n = 124 902). The presence of speciﬁc phobia as
deﬁned by the Diagnostic and Statistical Manual of Mental Disorders, fourth edition was evaluated using the World
Health Organization Composite International Diagnostic Interview.
Results. The cross-national lifetime and 12-month prevalence rates of speciﬁc phobia were, respectively, 7.4% and 5.5%,
being higher in females (9.8 and 7.7%) than in males (4.9% and 3.3%) and higher in high- and higher-middle-income
countries than in low-/lower-middle-income countries. The median age of onset was young (8 years). Of the
12-month patients, 18.7% reported severe role impairment (13.3–21.9% across income groups) and 23.1% reported any
treatment (9.6–30.1% across income groups). Lifetime co-morbidity was observed in 60.5% of those with lifetime speciﬁc
phobia, with the onset of speciﬁc phobia preceding the other disorder in most cases (72.6%). Interestingly, rates of
impairment, treatment use and co-morbidity increased with the number of fear subtypes.
Conclusions. Speciﬁc phobia is common and associated with impairment in a considerable percentage of cases.
Importantly, speciﬁc phobia often precedes the onset of other mental disorders, making it a possible early-life indicator
of psychopathology vulnerability.
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Introduction
Speciﬁc phobia is one of the most common mental dis-
orders in the general population with lifetime and
12-month prevalence estimates in representative popu-
lation surveys ranging from 7.7 to 12.5% and from 2.0
to 8.8%, respectively (Kessler et al. 1994, 2005; Bijl et al.
1998; Alonso et al. 2004; Wells et al. 2006; Stinson et al.
2007; Grenier et al. 2011; de Graaf et al. 2012). In add-
ition, prospective studies have shown high incidence
rates for speciﬁc phobia. Angst et al. (2016) found a
cumulative incidence of 26.9% between the ages of 20
and 50 years. Bijl et al. (2002) found a 1-year incidence
rate of 2.20 new cases per 100 person-years. Grant et al.
(2009) found a lower 1-year incidence rate of 0.44 new
cases per 100 person-years. Interestingly, prevalence
rates (e.g. Kessler et al. 1994; Bijl et al. 1998; Stinson
et al. 2007) and incidence rates (Bijl et al. 2002; Angst
et al. 2016) have been found to be higher in females
than in males. Also, prevalence rates have been
shown to decrease with age (e.g. Stinson et al. 2007;
Sigström et al. 2016).
Because of its high prevalence, lifetime persistence
(e.g. Goisman et al. 1998), associated impairment and
high lifetime co-morbidity rate with other disorders,
speciﬁc phobia is important from both an epidemio-
logical and a clinical perspective. Previous work has
shown considerable role impairment in those with
speciﬁc phobia, with 34.2% reporting signiﬁcant
role impairments in their daily life, compared with
26.5% in agoraphobia and 33.5% in social phobia
(Magee et al. 1996). Depla et al. (2008) showed that
up to 59.2% of patients reported interference with
their daily life. Using data from the National
Epidemiologic Survey on Alcohol and Related
Conditions (NESARC), Stinson et al. (2007) showed
that impairment levels in speciﬁc phobia were compar-
able with other anxiety and substance use disorders.
However, other studies have found low disability in
speciﬁc phobia compared with other disorders (e.g.
Wells et al. 2006; Ormel et al. 2008) and it has been
suggested that observed functional impairment in
speciﬁc phobia can be partly explained by high co-
occurrence with other disorders (Comer et al. 2011).
Nevertheless, the restricted lifestyle resulting from
fear and avoidance in speciﬁc phobia is likely to con-
tribute independently to functional impairment.
Previous surveys have shown that co-morbidity
rates between speciﬁc phobia and other mental disor-
ders are high (Kessler et al. 1996, 1997), with estimated
rates of up to 83.4% (Magee et al. 1996). Interestingly,
these retrospective studies showed that in the majority
of co-morbid cases, the onset of speciﬁc phobia pre-
cedes the other disorder(s) (Kessler et al. 1996, 1997;
Magee et al. 1996). Prospective work has shown that
speciﬁc phobia is associated with a higher odds of
later depressive, anxiety and eating disorders
(Goodwin, 2002; Bittner et al. 2004; Trumpf et al.
2010; Lieb et al. 2016) but not of later substance use dis-
orders (Zimmermann et al. 2003). Grant et al. (2009)
showed that speciﬁc phobia at baseline was associated
with an increased incidence of other anxiety disorders.
However, these associations could also be explained
by other baseline disorders and sociodemographic
factors.
Relatively effective treatments, such as behaviour
therapy and cognitive therapy, are available for
speciﬁc phobia (Choy et al. 2007). However, despite
speciﬁc phobia patients’ need for care, only a minority
of patients seek treatment in their lifetime (Magee et al.
1996: 46.6%; Stinson et al. 2007: 8.0%). In addition, it
has been shown that speciﬁc phobia patients that do
seek treatment take much longer to do so compared
with other anxiety disorders (Iza et al. 2013; ten Have
et al. 2013).
Within speciﬁc phobia, the Diagnostic and Statistical
Manual of Mental Disorders (DSM) distinguishes
between different subtypes: animal (e.g. bugs, snakes),
natural environment (e.g. heights, weather), blood-
injection-injury, situational (e.g. ﬂying on a plane,
enclosed spaces) and other (e.g. vomiting, choking).
Previously phobia subtypes have been shown to differ
in terms of, for example, prevalence, impairment levels
and co-morbidity rates (e.g. Fredrikson et al. 1996;
Becker et al. 2007; Depla et al. 2008; LeBeau et al.
2010). Also, most patients have more than one subtype
(Curtis et al. 1998; Burstein et al. 2012) and increasing
numbers of subtypes have been shown to be associated
with more co-morbidity, impairment and treatment-
seeking (e.g. Curtis et al. 1998; Stinson et al. 2007;
Burstein et al. 2012).
Although the above-described ﬁndings indicate that
speciﬁc phobia is a highly relevant condition that
deserves attention from both researchers and clini-
cians, they all come from surveys in Western, high-
income countries. This makes it hard to judge the
universal relevance of speciﬁc phobia as an impairing
condition and a marker for increased psychopathology
risk. In this study we therefore took a cross-national
approach, combining World Mental Health (WMH)
population survey data from 22 low-/lower-middle-
income, upper-middle-income and high-income coun-
tries (n = 124 902) to gain a more complete insight
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into the epidemiological characteristics of speciﬁc pho-
bia around the world.
Method
Sample
Data came from 25 World Health Organization (WHO)
WMH surveys, conducted in 22 countries (online
Supplementary Appendix Table S1). Of these coun-
tries, ﬁve are classiﬁed by the World Bank (World
Bank, 2008) as low-/lower-middle-income countries
[Colombia, Iraq, Nigeria, Peru and the People’s
Republic of China (PRC)], six as upper-middle-income
countries [Brazil, Bulgaria, Colombia (Medellín),
Lebanon, Mexico and Romania] and 12 as high-income
countries (Belgium, France, Germany, Italy, Japan, the
Netherlands, New Zealand, Northern Ireland, Poland,
Portugal, Spain and the USA). The sample sizes of the
surveys ranged from 2357 (Romania) to 12 790 (New
Zealand) and the total combined sample size was
124 902. Most surveys were based on nationally repre-
sentative stratiﬁed multistage clustered area probabil-
ity samples of household residents. All respondents
were aged 18 years or older. Response rates ranged
from 45.9% (France) to 97.2% (Colombia) and the aver-
age weighted response rate across countries was 69.3%.
The surveys were conducted face to face by trained lay
interviewers. The same standardized procedures for
interviewer training, translation of the used study
materials and quality control were used in all countries
(Kessler & Üstün, 2008). To reduce the burden of the
interview it was often divided into two parts. In part
I, core mental disorders were assessed. In part II, add-
itional disorders and correlates were assessed. All
respondents completed part I (n = 124 902). Part II
(n = 60 345) was additionally administered to a sub-
sample of respondents meeting criteria for any part I
disorder and in a probability subsample of the other
part I respondents. Part II responses were weighted
by the inverse of their probability of selection into
the part II sample to adjust for any differential sam-
pling. All respondents provided informed consent
prior to the interview and the study protocols were
approved by the institutional review boards of the
organizations coordinating the surveys.
Measures
Diagnostic assessments
The lifetime and 12-month prevalence and age of
onset (AOO) of speciﬁc phobia as deﬁned in the
DSM-IV were evaluated with the WHO Composite
International Diagnostic Interview (CIDI, Kessler &
Üstün, 2004). In the screening section, respondents
were shown a list of six speciﬁc fears [animals, still
water/weather events, blood/injuries/medical experi-
ences (BIM), closed spaces, high places, ﬂying] and
were asked if they ever had a strong fear of any of
these things. If any speciﬁc fear was reported in the
screening section, the speciﬁc phobia section was
administered. The CIDI was also used to assess other
psychiatric disorders, including mood (major depres-
sive, dysthymic, bipolar-I, bipolar-II and subthreshold
bipolar disorder), anxiety (agoraphobia, social phobia,
generalized anxiety, panic, post-traumatic stress and
separation anxiety), substance use (alcohol and drug
abuse, alcohol and drug dependence with abuse) and
behaviour disorders (attention-deﬁcit/hyperactivity,
oppositional-deﬁant, conduct, intermittent explosive
disorder). The WMH interview translation, back-
translation and harmonization were done by culturally
competent bilingual clinicians, who reviewed, mod-
iﬁed and approved the key phrases describing the
assessed symptoms (Harkness et al. 2008). Masked clin-
ical reappraisal with a standardized clinical interview
showed fair agreement for speciﬁc phobia (area
under the receiver operating curve = 0.67; Haro et al.
2006).
Healthcare use
The services module of the WMH-CIDI v3.0 (Kessler &
Üstün, 2004) was used to assess if respondents ever
received treatment for emotion regulation problems,
psychological distress, anxiety or substance use. If
respondents reported ever receiving such care,
follow-up questions were asked about their age at
the ﬁrst and last treatment and about the treatment
they received in the past 12 months. Different sectors
of treatment were distinguished. The specialty mental
health sector included psychiatrists, psychologists or
any other non-psychiatrist mental health specialists
(social workers, counsellors in specialty mental health
settings, mental health helplines, overnight hospital
admissions for mental health or substance-related pro-
blems). The general medical sector included general
practitioners, other medical doctors, nurses, occupa-
tional therapists or any other healthcare professional.
The human services sector included religious or spirit-
ual advisors, social workers or counsellors in other set-
tings than the specialty mental health sector. The
complementary and alternative medicine sector
included any other type of healer (e.g. herbal healers,
self-help groups).
Impairment
A modiﬁed version of the Sheehan Disability Scales
(SDS; Leon et al. 1997) was used to assess 12-
month role-functioning. Respondents were asked to
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remember the month in which their speciﬁc phobia
was most severe and to rate its interference with func-
tioning in four domains (home management, ability to
work, relationships and social life) on a 10-point scale.
Those with a score of 7 or higher on one or more SDS
domains were classiﬁed as severely impaired.
Respondents with 12-month speciﬁc phobia were also
asked how many of the 365 days in the past 12 months
they had been totally unable to work or carry out their
normal activities because of their speciﬁc phobia.
Demographic factors
The following demographic factors were investigated:
age group (18–29 years, 30–44 years, 45–59 years and
60+ years), gender, employment status [employed,
student, homemaker, retired, other (unemployed, tem-
porarily laid off, maternity leave, illness/sick leave, and
disabled)], marital status (currently married, divorced/
separated/widowed, never married), education level
(no education, some primary, ﬁnished primary, some
secondary, ﬁnished secondary, some college, ﬁnished
college) and household income (low, low-average,
high-average and high). Income categories were
based on the quartiles of country-speciﬁc gross house-
hold income distributions (Levinson et al. 2010).
Statistical analyses
Analyses of prevalence, AOO and impairment were
carried out for the cross-national sample, each coun-
try-income group, each country survey and cross-
national gender groups. Cross-tabulations were used
to estimate the lifetime, 12-month and 30-day preva-
lence. Only lifetime prevalence rates were calculated
for subtypes of speciﬁc phobia and the prevalence of
speciﬁc phobia with one to more than four lifetime
subtypes.
The 12-month prevalence of speciﬁc phobia among
lifetime cases was used as an indicator of recurrence
or chronicity: e.g. a disorder can have a high lifetime
prevalence, but a low level of recurrence as shown
by a low 12-month prevalence among lifetime cases.
The 30-day prevalence among 12-month cases was cal-
culated as an indicator of disorder duration: e.g. a dis-
order can have a high 12-month prevalence, but a
limited duration, as shown by a low 30-day preva-
lence. The percentages of lifetime and 12-month
co-morbidity in lifetime cases and the percentages of
12-month co-morbidity in 12-month cases were esti-
mated. In addition, the percentages of cases in which
speciﬁc phobia was the temporally primary disorder
were calculated. The percentages of 12-month speciﬁc
phobia cases with severe role impairment and health-
care use across sectors were calculated with cross-
tabulation. The mean number of days out of role was
calculated for all 12-month speciﬁc phobia cases com-
bined and for subsamples of 12-month cases, split
out by their highest reported domain of role impair-
ment. Percentages of lifetime co-morbidity, 12-month
impairment and healthcare use were calculated for
each subtype and groups with one to more than four
lifetime subtypes.
The AOO and the projected risk at age 75 years were
estimated with the two-part actuarial method imple-
mented in SAS. The actuarial method assumes a con-
stant conditional risk of onset in a given year of life
across cohorts and allows for accurate estimations of
the onset timings within a year (Halli et al. 1992).
Associations of lifetime speciﬁc phobia with demo-
graphic factors were analysed with survival models,
adjusted for age cohort, gender, person-years and
country. Associations of 30-day speciﬁc phobia with
demographic factors were analysed with logistic
regression models, adjusted for time since speciﬁc pho-
bia onset, AOO, gender and country. Associations of
demographic factors with recurrence (12-month pre-
valence among lifetime cases) and duration (30-day
prevalence among 12-month cases) were analysed
with logistic regression, adjusted for time since speciﬁc
phobia onset, AOO, gender and country. The distribu-
tions of AOO and of sociodemographic variables were
calculated for groups with different subtypes and sub-
groups with one to more than four lifetime subtypes.
All analyses were weighted to adjust for differential
selection probabilities within households, to match the
samples to population sociodemographic distributions
and to adjust for non-response (Kessler & Üstün, 2008).
Design-adjusted standard errors were estimated using
the Taylor series linearization method (Wolter, 1985),
implemented in SAS 9.4 (SAS Institute Inc., USA).
Design-adjusted Wald χ2 tests were used to test the
multivariate statistical signiﬁcance of sets of predictors.
Results
Prevalence
Lifetime speciﬁc phobia prevalence ranged from 2.6%
to 12.5% across countries (Table 1) and the averaged
cross-national lifetime prevalence was 7.4% for the
whole sample [median = 6.8%, interquartile range
(IQR) = 4.8–10.2%], 4.9% for the male and 9.8% for
the female subsample. The prevalence was 8.0–8.1%
in high-income and upper-middle-income countries
and 5.7% in the low-/lower-middle-income countries.
The overall mean 12-month prevalence was 5.5% in
the whole sample (median = 5.0%, IQR = 3.8–7.6%),
3.3% among males and 7.7% among females. The
12-month prevalence differed across countries (1.7–
10.6%) and income groups (4.0–6.4%), with the lowest
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prevalence in the low-/lower-middle-income group
(4.0%). The overall mean 30-day prevalence was 3.9%
in the total sample, with differences across gender
(males: 2.1%; females: 5.5%), countries (0.9–8.8%) and
income groups (2.4–4.8%), with the lowest prevalence
(2.4%) in the low-/lower-middle-income countries.
Of speciﬁc phobia subtypes (Table 2), animal fear
had the highest cross-national lifetime prevalence
(3.8%), followed by BIM (3.0%), high places (2.8%)
and still water or weather events fear (2.3%). Fear of
ﬂying had the lowest prevalence (1.3%). The low-/
lower-middle-income countries showed the lowest
Table 1. Prevalence of DSM-IV speciﬁc phobia in the World Mental Health surveys
Country
Lifetime
prevalence
12-month
prevalence
30-day
prevalence
12-month prevalence
of speciﬁc phobia
among lifetime cases
30-day prevalence of
speciﬁc phobia among
12-month cases
Part 1
sample
sizes, n
Low-/lower-middle-income
countries
5.7 (0.2) 4.0 (0.2) 2.4 (0.1) 70.6 (1.6) 58.7 (1.8) 31 773
Colombia 12.5 (0.8) 8.9 (0.8) 5.7 (0.5) 71.5 (2.6) 64.2 (3.2) 4426
Iraq 4.2 (0.4) 3.8 (0.4) 3.2 (0.4) 90.4 (3.5) 82.4 (4.2) 4332
Nigeria 5.9 (0.5) 4.4 (0.3) 2.2 (0.2) 74.5 (3.2) 49.6 (3.8) 6752
Peru 6.6 (0.4) 4.6 (0.3) 2.5 (0.2) 69.7 (4.8) 54.4 (3.6) 3930
PRC China 2.6 (0.3) 1.7 (0.3) 1.0 (0.2) 63.2 (3.6) 56.9 (8.0) 5201
PRC Shen Zhen 4.0 (0.3) 2.2 (0.3) 0.9 (0.1) 54.9 (5.4) 42.6 (4.1) 7132
Upper-middle-income
countries
8.0 (0.2) 6.4 (0.2) 4.8 (0.2) 80.6 (1.1) 75.1 (1.5) 24 612
Brazil 12.5 (0.6) 10.6 (0.5) 8.8 (0.5) 85.2 (1.6) 82.9 (2.6) 5037
Bulgaria 5.8 (0.3) 3.9 (0.3) 3.1 (0.3) 68.1 (3.3) 78.3 (2.9) 5318
Colombia (Medellín) 10.2 (0.8) 8.3 (0.7) 6.4 (0.6) 81.7 (3.1) 76.9 (3.0) 3261
Lebanon 7.1 (0.6) 6.6 (0.5) 5.0 (0.5) 93.0 (1.7) 75.9 (3.8) 2857
Mexico 7.0 (0.5) 5.2 (0.4) 2.8 (0.2) 74.3 (2.6) 54.3 (3.9) 5782
Romania 3.8 (0.5) 3.3 (0.5) 2.8 (0.5) 86.1 (4.9) 84.3 (5.2) 2357
High-income countries 8.1 (0.1) 5.9 (0.1) 4.2 (0.1) 73.2 (0.8) 71.9 (0.8) 68 517
Belgium 6.8 (1.0) 5.0 (0.7) 3.6 (0.5) 73.2 (3.5) 71.1 (5.4) 2419
France 10.7 (0.6) 7.7 (0.7) 6.0 (0.5) 71.7 (3.8) 78.3 (3.3) 2894
Germany 9.9 (0.7) 6.9 (0.6) 4.8 (0.3) 69.5 (2.6) 70.6 (3.5) 3555
Italy 5.4 (0.5) 3.9 (0.4) 2.8 (0.3) 72.6 (2.2) 72.6 (2.8) 4712
Japan 3.4 (0.3) 2.3 (0.2) 1.8 (0.2) 68.0 (4.5) 77.9 (4.7) 4129
New Zealand 10.9 (0.4) 7.6 (0.3) 5.2 (0.3) 70.2 (1.4) 68.6 (2.1) 12 790
Northern Ireland 9.7 (0.6) 7.2 (0.5) 5.2 (0.4) 74.6 (2.1) 71.6 (2.7) 4340
Poland 3.4 (0.2) 2.5 (0.2) 1.7 (0.1) 72.8 (2.9) 67.6 (3.0) 10 081
Portugal 10.6 (0.6) 8.6 (0.5) 7.0 (0.5) 81.3 (1.8) 81.1 (2.0) 3849
Spain 4.8 (0.4) 3.8 (0.4) 2.9 (0.3) 80.1 (3.3) 74.6 (3.2) 5473
Spain (Murcia) 5.4 (0.5) 4.7 (0.4) 3.7 (0.3) 86.9 (2.5) 78.4 (3.5) 2621
The Netherlands 7.6 (0.7) 5.4 (0.6) 4.3 (0.6) 70.5 (3.2) 79.4 (3.9) 2372
USA 12.5 (0.4) 9.1 (0.4) 6.3 (0.4) 73.0 (2.2) 68.8 (1.9) 9282
All countries combined 7.4 (0.1) 5.5 (0.1) 3.9 (0.1) 74.2 (0.6) 70.2 (0.7) 124 902
All males 4.9 (0.1) 3.3 (0.1) 2.1 (0.1) 65.8 (1.2) 64.7 (1.4) 56 526
All females 9.8 (0.1) 7.7 (0.1) 5.5 (0.1) 78.2 (0.6) 72.4 (0.8) 68 376
Comparison between
countriesa
χ224 = 47.7*,
p < 0.001
χ224 = 39.4*,
p < 0.001
χ224 = 39.4*,
p < 0.001
χ224 = 7.8*,
p < 0.001
χ224 = 7.2*,
p < 0.001
Comparison between low-,
middle- and high-income
country groupsa
χ22 = 51.1*,
p < 0.001
χ22 = 56.8*,
p < 0.001
χ22 = 103.8*,
p < 0.001
χ22 = 19.1*,
p < 0.001
χ22 = 26.4*,
p < 0.001
Comparison between
gendersa
χ21 = 722.1*,
p < 0.001
χ21 = 855.3*,
p < 0.001
χ21 = 735.5*,
p < 0.001
χ21 = 84.2*,
p < 0.001
χ21 = 23.7*,
p < 0.001
Data are given as percentage (standard error) unless otherwise indicated.
DSM-IV, Diagnostic and Statistical Manual of Mental Disorders, fourth edition; PRC, People’s Republic of China.
a χ2 Test of homogeneity to determine if there is variation in prevalence estimates.
* p < 0.05 (two-sided test).
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Table 2. Lifetime prevalence of DSM-IV speciﬁc phobia subtypes and cases with different numbers of co-occurring subtypes in the World Mental Health surveys
Kinds of subtypes Numbers of subtypes
Country Animal
Still water,
weather
events
Blood,
injuries,
medical
experiences
Closed
spaces
High
places Flying
One
subtype
Two
subtypes
Three
subtypes
Four
or more
subtypes
Part 1
sample
sizes, n
Low-/lower-middle-income
countries
3.4 (0.1) 2.1 (0.1) 2.2 (0.1) 1.6 (0.1) 2.0 (0.1) 0.6 (0.1) 2.7 (0.1) 1.3 (0.1) 0.8 (0.1) 0.9 (0.1) 31 773
Colombia 8.1 (0.6) 6.2 (0.5) 6.0 (0.5) 5.2 (0.4) 7.1 (0.6) 2.2 (0.3) 3.1 (0.4) 3.0 (0.4) 2.3 (0.3) 4.1 (0.4) 4426
Iraq 2.3 (0.3) 1.3 (0.3) 1.4 (0.3) 0.7 (0.2) 0.9 (0.2) 0.3 (0.1) 2.8 (0.4) 0.7 (0.1) 0.4 (0.1) 0.3 (0.1) 4332
Nigeria 3.7 (0.3) 2.2 (0.3) 1.6 (0.2) 1.4 (0.3) 1.0 (0.1) 0.4 (0.1) 3.4 (0.3) 1.4 (0.2) 0.6 (0.1) 0.5 (0.1) 6752
Peru 3.6 (0.3) 2.0 (0.2) 2.6 (0.2) 1.4 (0.2) 1.7 (0.2) 0.6 (0.2) 3.7 (0.4) 1.4 (0.2) 0.9 (0.1) 0.6 (0.1) 3930
PRC China 1.4 (0.2) 0.4 (0.1) 0.9 (0.2) 0.4 (0.1) 1.0 (0.2) 0.2 (0.1) 1.5 (0.3) 0.7 (0.2) 0.3 (0.1) 0.1 (0.1) 5201
PRC Shen Zhen 2.1 (0.2) 1.0 (0.2) 1.8 (0.2) 1.0 (0.2) 1.3 (0.2) 0.4 (0.1) 2.1 (0.2) 1.0 (0.1) 0.4 (0.1) 0.4 (0.1) 7132
Upper-middle-income
countries
4.4 (0.2) 2.8 (0.1) 3.0 (0.2) 2.3 (0.1) 3.0 (0.1) 1.2 (0.1) 3.6 (0.2) 2.0 (0.1) 1.0 (0.1) 1.3 (0.1) 24 612
Brazil 7.0 (0.4) 3.7 (0.3) 4.4 (0.5) 3.4 (0.3) 4.8 (0.4) 1.8 (0.2) 5.9 (0.3) 3.1 (0.3) 1.7 (0.2) 1.8 (0.2) 5037
Bulgaria 3.0 (0.3) 2.2 (0.3) 2.4 (0.2) 1.0 (0.1) 1.7 (0.2) 0.4 (0.1) 2.6 (0.3) 2.0 (0.2) 0.6 (0.1) 0.6 (0.1) 5318
Colombia (Medellín) 6.5 (0.6) 4.4 (0.5) 4.5 (0.5) 4.6 (0.5) 5.7 (0.6) 2.5 (0.3) 2.9 (0.4) 2.1 (0.4) 1.8 (0.3) 3.3 (0.4) 3261
Lebanon 2.8 (0.2) 2.9 (0.4) 2.1 (0.4) 1.1 (0.3) 1.0 (0.2) 0.5 (0.1) 4.9 (0.5) 1.5 (0.2) 0.5 (0.2) 0.2 (0.0) 2857
Mexico 4.0 (0.3) 2.2 (0.3) 2.4 (0.3) 2.1 (0.3) 2.7 (0.3) 1.1 (0.2) 3.4 (0.4) 1.7 (0.2) 0.9 (0.1) 1.1 (0.2) 5782
Romania 1.7 (0.4) 2.0 (0.4) 2.0 (0.4) 1.1 (0.3) 1.8 (0.3) 0.4 (0.2) 1.3 (0.3) 1.2 (0.2) 0.6 (0.2) 0.7 (0.2) 2357
High income 3.7 (0.1) 2.2 (0.1) 3.4 (0.1) 2.4 (0.1) 3.1 (0.1) 1.7 (0.1) 3.7 (0.1) 2.0 (0.1) 1.3 (0.1) 1.1 (0.1) 68 517
Belgium 2.5 (0.5) 1.7 (0.4) 2.2 (0.4) 1.3 (0.5) 2.3 (0.6) 0.8 (0.2) 4.4 (0.6) 1.3 (0.3) 0.9 (0.3) 0.3 (0.2) 2419
France 3.8 (0.4) 2.8 (0.3) 3.9 (0.4) 2.7 (0.4) 3.6 (0.4) 1.3 (0.3) 6.2 (0.5) 2.3 (0.4) 1.4 (0.2) 0.8 (0.2) 2894
Germany 3.5 (0.4) 1.7 (0.4) 3.9 (0.4) 2.0 (0.3) 2.5 (0.2) 1.7 (0.2) 6.0 (0.5) 2.7 (0.3) 0.9 (0.2) 0.3 (0.1) 3555
Italy 2.0 (0.2) 1.3 (0.2) 2.2 (0.3) 1.5 (0.2) 1.4 (0.2) 1.0 (0.2) 3.0 (0.3) 1.3 (0.2) 0.7 (0.2) 0.4 (0.1) 4712
Japan 2.0 (0.2) 1.5 (0.2) 1.4 (0.2) 1.1 (0.2) 1.2 (0.2) 0.7 (0.1) 1.3 (0.2) 0.9 (0.1) 0.5 (0.1) 0.7 (0.2) 4129
New Zealand 5.0 (0.3) 2.2 (0.2) 4.7 (0.2) 3.4 (0.2) 4.7 (0.2) 2.2 (0.2) 4.7 (0.2) 3.0 (0.2) 2.0 (0.2) 1.2 (0.1) 12 790
Northern Ireland 4.6 (0.4) 3.9 (0.4) 4.8 (0.4) 3.5 (0.4) 4.6 (0.4) 2.3 (0.3) 3.3 (0.4) 2.3 (0.2) 1.7 (0.2) 2.4 (0.3) 4340
Poland 1.5 (0.1) 0.9 (0.1) 1.3 (0.1) 0.8 (0.1) 1.4 (0.1) 0.6 (0.1) 1.7 (0.1) 0.8 (0.1) 0.5 (0.1) 0.4 (0.1) 10 081
Portugal 6.1 (0.5) 4.1 (0.4) 4.6 (0.4) 3.6 (0.3) 4.3 (0.3) 1.9 (0.2) 3.8 (0.4) 2.8 (0.3) 1.9 (0.2) 2.2 (0.3) 3849
Spain 2.1 (0.2) 1.1 (0.2) 1.4 (0.2) 1.3 (0.2) 1.1 (0.2) 0.7 (0.1) 3.0 (0.4) 1.0 (0.2) 0.4 (0.1) 0.3 (0.1) 5473
Spain (Murcia) 2.6 (0.3) 0.9 (0.2) 0.7 (0.2) 1.7 (0.4) 1.5 (0.3) 0.7 (0.2) 3.5 (0.3) 1.1 (0.3) 0.6 (0.2) 0.1 (0.1) 2621
The Netherlands 2.4 (0.4) 1.5 (0.3) 2.9 (0.5) 1.4 (0.3) 1.7 (0.3) 1.0 (0.3) 5.4 (0.6) 1.4 (0.3) 0.7 (0.2) 0.1 (0.1) 2372
USA 6.6 (0.3) 4.3 (0.2) 6.0 (0.3) 4.4 (0.2) 5.9 (0.3) 3.8 (0.2) 4.1 (0.3) 3.1 (0.2) 2.3 (0.2) 2.9 (0.2) 9282
All countries combined 3.8 (0.1) 2.3 (0.1) 3.0 (0.1) 2.2 (0.1) 2.8 (0.1) 1.3 (0.0) 3.4 (0.1) 1.8 (0.0) 1.1 (0.0) 1.1 (0.0) 124 902
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prevalence rates for all subtypes (0.6–3.4%) and consid-
erably higher prevalence rates in upper-middle-income
countries (1.2–4.4%) and high-income countries (1.7–
3.7%). The clearest difference was seen for fear of
ﬂying, which had an almost three times higher preva-
lence in high-income (1.7%) than in low-/lower-
middle-income (0.6%) countries. All subtypes were
most common in females. Of the cross-national sample,
3.4% reported a single subtype, 1.8% reported two sub-
types, 1.1% reported three subtypes and 1.1% reported
more than four subtypes. Higher numbers of subtypes
were more common among females than males.
Recurrence and duration
The averaged prevalence of 12-month speciﬁc phobia
among lifetime speciﬁc phobia cases was 74.2% for
the whole cross-national sample (median = 73.0%,
IQR = 70.2–81.3%; Table 1). The averaged prevalence
of 30-day speciﬁc phobia among 12-month cases was
70.2% for the cross-national sample (median = 72.6%,
IQR = 67.6–78.3%). Both prevalence rates were higher
in females than in males. In addition, the 30-day preva-
lence among 12-month cases was the only that differed
notably across income groups, with the lowest rate in
the low-/low-middle-income group (58.7%).
AOO
The median AOO was 8 years (IQR = 5–13 years; online
Supplementary Appendix Table S2) and differed
slightly across surveys (IQR = 8–9 years). The cross-
national projected risk at age 75 years was only 0.7%
higher than the observed lifetime prevalence rate
(8.1% v. 7.4%), reﬂecting speciﬁc phobia’s young
AOO distribution. Early AOO was most common for
all subtypes, but especially common for fear of still
water/weather (Table 3; 37.1%), animals (36.6%) and
closed spaces (35.2%). A slightly older-onset distribu-
tion was seen for fear of ﬂying and high places.
Early-onset rates increased and late-onset rates
decreased with the number of fears.
Co-morbidity
In 60.5% of lifetime speciﬁc phobia cases, at least one
other lifetime disorder was present, with 34.3% having
a co-morbid mood disorder, 41.2% an anxiety disorder,
15.9% a substance use disorder and 17.4% an impulse-
control disorder (Table 4). In those with 12-month
co-morbidity of speciﬁc phobia with any other dis-
order, co-morbid anxiety disorders were most common
(29.6%), followed by mood disorders (21.0%). Speciﬁc
phobia preceded the other disorders in the majority
of co-morbid cases (71.6–92.2%). Lifetime co-morbidity
with any other disorder ranged from 60.6% to 73.0%A
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Table 3. Sociodemographic characteristics, impairment, co-morbidity and treatment use for each speciﬁc phobia subtype and for groups of patients with different numbers of phobias
Kinds of lifetime phobias Number of lifetime phobias
Animal
Still water,
weather
Blood,
injuries, medical
experiences
Closed
spaces
High
places Flying
One
phobia
Two
phobias
Three
phobias
Four
or more
phobias
Age, years
18–29 34.1 (0.9) 27.5 (1.1) 32.4 (1.0) 24.1 (1.0) 23.4 (0.9) 23.4 (1.3) 32.6 (0.9) 28.8 (1.3) 25.2 (1.5) 27.9 (1.4)
30–44 33.1 (0.8) 30.0 (1.0) 32.7 (0.9) 33.6 (1.1) 34.6 (1.0) 33.0 (1.4) 31.3 (0.9) 33.0 (1.2) 35.5 (1.5) 32.1 (1.5)
45–59 22.0 (0.8) 27.3 (1.0) 24.4 (0.9) 28.3 (1.0) 29.1 (0.9) 29.4 (1.3) 22.5 (0.7) 23.4 (1.1) 27.9 (1.5) 29.1 (1.4)
60+ 10.8 (0.5) 15.2 (0.8) 10.5 (0.6) 14.0 (0.7) 12.8 (0.7) 14.3 (0.9) 13.6 (0.6) 14.7 (0.9) 11.5 (1.0) 11.0 (0.9)
Gender
Male 25.3 (0.8) 26.5 (1.0) 35.7 (1.0) 27.7 (1.1) 34.8 (1.0) 29.6 (1.3) 36.0 (0.9) 31.0 (1.2) 28.3 (1.5) 26.5 (1.4)
Female 74.7 (0.8) 73.5 (1.0) 64.3 (1.0) 72.3 (1.1) 65.2 (1.0) 70.4 (1.3) 64.0 (0.9) 69.0 (1.2) 71.7 (1.5) 73.5 (1.4)
Marital status
Married 58.6 (0.9) 61.7 (1.1) 58.4 (1.0) 60.3 (1.2) 61.4 (1.0) 63.9 (1.4) 59.6 (0.9) 59.6 (1.3) 61.8 (1.5) 60.4 (1.6)
Never married 28.1 (0.9) 22.0 (1.1) 28.4 (0.9) 22.9 (1.0) 23.3 (1.0) 20.1 (1.3) 28.1 (0.9) 26.1 (1.2) 23.9 (1.4) 22.9 (1.5)
Separated/widowed/divorced 13.2 (0.6) 16.2 (0.8) 13.2 (0.6) 16.7 (0.8) 15.2 (0.6) 16.0 (0.9) 12.3 (0.6) 14.3 (0.8) 14.2 (1.1) 16.7 (1.0)
Employment status
Student 5.3 (0.6) 3.9 (0.6) 4.9 (0.6) 3.7 (0.5) 3.0 (0.4) 3.6 (0.6) 6.5 (0.7) 5.1 (0.7) 3.6 (0.8) 2.4 (0.6)
Working 57.2 (1.1) 53.9 (1.3) 59.6 (1.2) 55.1 (1.3) 58.1 (1.1) 55.4 (1.7) 57.7 (1.4) 58.4 (1.5) 60.8 (1.7) 53.1 (1.8)
Retired 8.1 (0.6) 11.3 (0.8) 9.1 (0.8) 10.4 (0.9) 10.1 (0.7) 10.3 (1.0) 10.9 (0.8) 10.1 (0.9) 10.5 (1.3) 7.9 (0.9)
Homemaker 16.9 (0.8) 18.1 (1.0) 13.9 (0.8) 17.3 (1.0) 15.4 (0.7) 17.2 (1.3) 13.7 (0.9) 14.2 (1.0) 13.9 (1.2) 20.9 (1.4)
Other 12.5 (0.8) 12.8 (0.9) 12.6 (0.8) 13.6 (1.0) 13.4 (0.8) 13.4 (1.2) 11.1 (0.9) 12.2 (1.0) 11.1 (0.9) 15.7 (1.4)
Income
Low 30.1 (1.1) 31.4 (1.2) 31.1 (1.1) 32.5 (1.3) 30.7 (1.1) 33.2 (1.8) 27.0 (1.2) 29.0 (1.5) 32.7 (1.6) 34.6 (1.7)
Low-mid 25.4 (1.0) 26.2 (1.2) 25.1 (1.1) 24.9 (1.1) 25.9 (1.1) 23.7 (1.5) 23.8 (1.1) 23.8 (1.4) 25.3 (1.6) 27.8 (1.6)
Mid-high 24.3 (1.0) 24.5 (1.2) 23.8 (1.0) 22.4 (1.1) 24.6 (1.0) 22.7 (1.5) 27.5 (1.1) 26.3 (1.6) 22.8 (1.5) 20.4 (1.4)
High 20.2 (0.9) 17.9 (1.0) 20.0 (1.0) 20.2 (1.1) 18.8 (0.9) 20.4 (1.4) 21.7 (1.2) 20.9 (1.3) 19.2 (1.3) 17.2 (1.4)
Education level
None 2.6 (0.3) 3.1 (0.3) 1.8 (0.3) 2.0 (0.3) 1.8 (0.2) 1.1 (0.2) 2.6 (0.3) 2.4 (0.3) 2.0 (0.4) 1.8 (0.3)
Some primary 10.1 (0.5) 11.7 (0.7) 9.4 (0.6) 10.8 (0.7) 10.6 (0.6) 9.6 (0.9) 8.0 (0.5) 10.0 (0.9) 9.4 (0.9) 12.8 (1.0)
Complete primary 8.2 (0.5) 10.1 (0.7) 6.9 (0.5) 9.1 (0.7) 8.1 (0.5) 7.3 (0.8) 7.0 (0.5) 7.9 (0.7) 7.5 (0.8) 9.9 (1.0)
Some secondary 21.0 (0.7) 22.2 (1.0) 22.1 (0.8) 23.4 (0.9) 22.3 (0.8) 23.3 (1.4) 19.0 (0.8) 21.4 (1.1) 22.5 (1.4) 24.4 (1.4)
Complete secondary 27.8 (0.8) 29.4 (1.0) 31.5 (1.0) 27.6 (1.0) 29.5 (0.9) 29.1 (1.4) 31.1 (0.9) 29.0 (1.1) 31.9 (1.5) 26.3 (1.4)
Some college 16.9 (0.7) 13.7 (0.8) 16.2 (0.8) 15.2 (0.8) 14.3 (0.7) 16.1 (1.2) 16.6 (0.7) 15.1 (1.0) 13.6 (1.1) 16.4 (1.2)
Complete college 11.8 (0.6) 8.8 (0.6) 11.0 (0.6) 10.8 (0.7) 12.1 (0.7) 12.3 (0.9) 13.8 (0.6) 13.0 (0.8) 12.1 (1.1) 7.6 (0.9)
Age of onset
Early 36.6 (0.9) 37.1 (1.1) 33.4 (0.9) 35.2 (1.0) 32.6 (1.0) 32.9 (1.4) 23.1 (0.8) 31.3 (1.2) 37.7 (1.6) 43.1 (1.6)
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across subtypes (Table 3). Co-morbidity was highest
with anxiety (range: 41.9–58.3%) and mood disorders
(range: 34.7–43.6%). Co-morbidity rates were highest
in those with fear of closed spaces and ﬂying and
increased with the number of subtypes from 49.7%
(one subtype) to 82.1% (four or more subtypes).
Demographic correlates of speciﬁc phobia onset
In the combined sample, higher risk of lifetime onset of
speciﬁc phobia (Table 5) was observed in respondents
aged younger than 60 years compared with respon-
dents aged 60 years and older [odds ratio (OR)
1.5–1.8], in women compared with men (OR 2.0), in
homemakers and those with ‘other’ employment status
compared with employed respondents (OR 1.2–1.4), in
previously married compared with currently married
(OR 1.2), in those with some college or less education
compared with those who completed college (OR
1.3–1.7), and in those with low and low-average
income compared with those with a high income (OR
1.1–1.2). When analysed by income group (online
Supplementary Appendix Tables S3–S5), the following
associations with increased odds of lifetime speciﬁc
phobia onset were consistently observed: being in the
youngest age cohort (OR 1.3–2.0), being female (OR
1.5–2.3), having employment status ‘other’ (OR 1.3–
1.5) and having a lower education than ﬁnished college
(OR 1.2–1.9).
The age group distribution varied across subtypes
(Table 3), with most young persons in animal and
BIM phobia. The percentage of females was highest
in all subtype groups and increased with number of
subtypes. Employment status showed limited vari-
ation across subtypes, but the percentage of working
persons was markedly lower (53.1%) in those with
four or more subtypes compared with those with one
to three subtypes (57.7–60.8%). The percentages of
cases with completed college showed some variation
across subtypes (8.8–12.3%), but a more striking differ-
ence between those with four or more subtypes (7.6%)
and those with one to three subtypes (12.1–13.8%).
Income group distributions showed limited variation
across subtypes, but the percentages of low and low-
mid income increased with the number of subtypes.
Demographic correlates of persistence
Among lifetime cases, 12-month speciﬁc phobia preva-
lence (Table 5) was higher in those with early AOO
compared with those with late AOO (OR 1.4), in
women compared with men (OR 1.8), in those who
were retired or had employment status ‘other’ com-
pared with the employed (OR 1.3 and OR 1.5), in
those with some college or less compared with those
with ﬁnished college (OR 1.3–1.7), and in those with
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low income compared with those with high income
(OR 1.4). Only female gender was consistently
observed to be associated with an increased odds of
30-day prevalence among 12-month cases (OR 1.5–
1.9; online Supplementary Appendix Tables S3–S5).
Impairment
In the combined sample, 18.7% of 12-month speciﬁc
phobia cases reported severe role impairment in any
domain (online Supplementary Appendix Table S6),
with the highest percentage of severe impairment in
the home domain (10.3%) and the lowest in the rela-
tionship domain (7.9%). The percentages of severe
impairment differed across income groups on all
domains, except for work. The low-/lower-middle-
income group, especially Nigeria and PRC Shen
Zhen, showed the lowest percentages of severe impair-
ment. The upper-middle-income group showed the
highest percentages of severe impairment (range: 9.9–
14.4%). The mean number of days out of role in the
past year due to 12-month speciﬁc phobia was 12.2
(S.E. = 0.9). However, those with severe impairment in
any domain reported 29.1 days out of role (online
Supplementary Appendix Table S7), with the number
of days varying depending on the investigated domain
of impairment (34.6–47.9 days). The percentage of
cases reporting any impairment varied somewhat
across subtypes (52.1–57.3%; Table 3). However,
impairment rates increased with the number of fear
subtypes, with 11.6% reporting severe impairment in
those with one subtype and 20.6% in those with four
or more subtypes.
Treatment
Cross-nationally, the percentage of 12-month speciﬁc
phobia cases reporting any treatment was 23.1%.
Treatment was more common in those reporting severe
impairment (32.5%) compared with those reporting
mild or moderate impairment (21.1% and 22.8%,
respectively; online Supplementary Appendix Table
S8). Treatment rates differed across income groups,
with 9.6% in low-/lower-middle-income, 16.0% in
higher-middle-income and 30.1% in high-income coun-
tries. Overall treatment use showed some variation
across subtypes (Table 3), with the highest rates for
fear of ﬂying (28.4%), closed spaces (27.5%) and high
Table 4. Co-morbidity of speciﬁc phobia with other DSM-IV disorders
Speciﬁc phobia cases with co-morbid disorders
Mood
disordera
Anxiety
disorderb
Impulse-control
disorderc
Substance
use disorderd
Any mental
disordere
Lifetime co-morbidityf
Lifetime speciﬁc phobia diagnosis 34.3 (0.7) 41.2 (0.8) 17.4 (0.7) 15.9 (0.6) 60.5 (0.9)
12-month speciﬁc phobia 35.9 (0.9) 42.9 (0.9) 18.1 (0.7) 15.6 (0.6) 62.0 (1.0)
12-month co-morbidityg
12-month speciﬁc phobia 21.0 (0.7) 29.6 (0.8) 10.1 (0.6) 5.3 (0.4) 42.2 (1.0)
Temporal priority of speciﬁc phobiah
Lifetime speciﬁc phobia 89.3 (0.7) 71.6 (0.9) 72.5 (1.7) 92.2 (0.9) 72.6 (0.8)
12-month speciﬁc phobia 89.7 (0.8) 72.2 (1.1) 71.5 (2.0) 92.8 (1.0) 72.8 (1.0)
Data are given as percentage (standard error) unless otherwise indicated.
DSM-IV, Diagnostic and Statistical Manual of Mental Disorders, fourth edition.
a Respondents with major depressive episode or bipolar disorder (broad).
b Respondents with panic disorder, generalized anxiety disorder, social phobia, agoraphobia, post-traumatic stress disorder
or separation anxiety disorder.
c Respondents with intermittent explosive disorder, attention-deﬁcit disorder, conduct disorder, oppositional deﬁant dis-
order, binge-eating disorder or bulimia nervosa.
d Respondents with alcohol abuse with or without dependence or drug abuse with or without dependence.
e Respondents with any disorder listed above.
f Percentage of respondents with either lifetime or 12-month speciﬁc phobia who also meet lifetime criteria for at least one
of the other DSM-IV disorders.
g Percentage of respondents with 12-month speciﬁc phobia who also meet 12-month criteria for at least one of the other
disorders.
h Percentage of respondents with either lifetime or 12-month speciﬁc phobia and at least one of the other disorders, whose
age of onset of speciﬁc phobia is reported to be younger than the age of onset of all co-morbid disorders under consideration
(i.e. either mood, anxiety, substance use, impulse control or any disorder).
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Table 5. Bivariate associations between sociodemographics correlates and DSM-IV speciﬁc phobia (all countries combined)
Correlates
30-day speciﬁc
phobiaa
Lifetime speciﬁc
phobiab
12-month speciﬁc phobia
among lifetime casesc
30-day speciﬁc phobia
among 12-month casesc
Age cohort, years
18–29 1.5 (1.3–1.6)* 1.8 (1.7–2.0)* – –
30–44 1.4 (1.3–1.6)* 1.6 (1.4–1.7)* – –
45–59 1.4 (1.2–1.6)* 1.5 (1.4–1.6)* – –
60+ 1.0 1.0
Age cohort differenced χ23 = 54.5*, p < 0.001 χ
2
3 = 208.2*, p < 0.001
Age of onset
Early – – 1.4 (1.2–1.7)* 0.9 (0.8–1.1)
Early-average – – 1.1 (0.9–1.3) 0.9 (0.7–1.0)
Late-average – – 1.1 (0.9–1.3) 0.8 (0.7–1.0)*
Late – – 1.0 1.0
Age of onset differenced χ23 = 20.7*, p < 0.001 χ
2
3 = 7.4, p = 0.061
Time since onset, continuous – – 1.00 (0.99–1.00)* 1.01 (1.01–1.01)*
χ21 = 6.4*, p < 0.012 χ
2
1 = 19.6*, p < 0.001
Gender
Female 2.7 (2.5–3.0)* 2.0 (1.9–2.2)* 1.8 (1.6–2.1)* 1.3 (1.2–1.5)*
Male 1.0 1.0 1.0 1.0
Gender differenced χ21 = 617.2*, p < 0.001 χ
2
1 = 635.9*, p < 0.001 χ
2
1 = 88.1*, p < 0.001 χ
2
1 = 15.7*, p < 0.001
Employment status
Student 1.0 (0.8–1.2) 1.1 (1.0–1.3) 1.2 (0.9–1.7) 0.9 (0.7–1.2)
Homemaker 1.3 (1.2–1.5)* 1.2 (1.1–1.3)* 1.2 (1.0–1.5) 1.3 (1.1–1.6)*
Retired 1.1 (0.9–1.2) 1.1 (1.0–1.3) 1.3 (1.0–1.6)* 0.9 (0.7–1.2)
Othere 1.6 (1.5–1.8)* 1.4 (1.3–1.5)* 1.5 (1.2–1.8)* 1.3 (1.1–1.6)*
Employed 1.0 1.0 1.0 1.0
Employment status differenced χ24 = 90.4*, p < 0.001 χ
2
4 = 69.9*, p < 0.001 χ
2
4 = 21.0*, p < 0.001 χ
2
4 = 15.5*, p = 0.004
Marital status
Never married 1.0 (0.9–1.1) 1.1 (1.0–1.1) 1.1 (0.9–1.2) 1.0 (0.9–1.2)
Divorced/separated/widowed 1.2 (1.1–1.3)* 1.2 (1.1–1.3)* 1.1 (0.9–1.3) 1.1 (0.9–1.3)
Currently married 1.0 1.0 1.0 1.0
Marital status differenced χ22 = 16.1*, p < 0.001 χ
2
2 = 23.0*, p < 0.001 χ
2
2 = 1.0, p = 0.614 χ
2
2 = 1.0, p = 0.619
Education level
No education 1.7 (1.3–2.2)* 1.4 (1.1–1.6)* 1.7 (1.1–2.6)* 1.7 (1.1–2.6)*
Some primary 2.2 (1.9–2.5)* 1.7 (1.6–1.9)* 1.7 (1.2–2.2)* 1.4 (1.0–1.8)*
Finished primary 1.9 (1.6–2.3)* 1.5 (1.4–1.7)* 1.5 (1.1–2.0)* 1.4 (1.0–1.8)
Some secondary 1.7 (1.5–1.9)* 1.5 (1.4–1.6)* 1.3 (1.1–1.7)* 1.2 (0.9–1.5)
Finished secondary 1.5 (1.3–1.7)* 1.3 (1.2–1.4)* 1.3 (1.1–1.6)* 1.3 (1.0–1.6)*
Some college 1.4 (1.2–1.6)* 1.3 (1.2–1.4)* 1.3 (1.0–1.6)* 1.1 (0.8–1.4)
Finished college 1.0 1.0 1.0 1.0
Education level differenced χ26 = 117.8*, p < 0.001 χ
2
6 = 131.6*, p < 0.001 χ
2
6 = 16.7*, p = 0.010 χ
2
6 = 11.1, p = 0.086
Household income
Low 1.4 (1.2–1.6)* 1.2 (1.1–1.3)* 1.4 (1.1–1.6)* 1.3 (1.1–1.6)*
Low-average 1.2 (1.1–1.4)* 1.1 (1.0–1.2)* 1.2 (1.0–1.4) 1.2 (1.0–1.5)
High-average 1.1 (1.0–1.2) 1.0 (1.0–1.1) 1.1 (0.9–1.2) 1.1 (0.9–1.4)
High 1.0 1.0 1.0 1.0
Household income differenced χ23 = 38.7*, p < 0.001 χ
2
3 = 28.1*, p < 0.001 χ
2
3 = 14.4*, p = 0.003 χ
2
3 = 7.7, p = 0.053
nf 124 902 5 130 258 9583 7140
Data are given as odds ratio (95% conﬁdence interval).
DSM-IV, Diagnostic and Statistical Manual of Mental Disorders, fourth edition.
a These estimates are based on logistic regression adjusted for age, gender and country.
b These estimates are based on survival models adjusted for age cohorts, gender, person-years and country.
c These estimates are based on logistic regression adjusted for time since speciﬁc phobia onset, age of onset, gender and country.
d χ2 Test of signiﬁcant differences between blocks of sociodemographic variables.
e Includes, for example, looking for work or being disabled.
f Denominator n: 124 902 = total sample; 5 130 258 = number of person-years in the survival models; 9583 = number of lifetime
cases of speciﬁc phobia; 7140 = number of 12-month cases of speciﬁc phobia.
* p < 0.05 (two-sided test).
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places (26.0%). Also, rates of treatment use increased
from 16.7% in those with one subtype to 29.2% in
those with four or more subtypes.
Discussion
Speciﬁc phobia is a common mental disorder with
a cross-national lifetime prevalence of 7.4%.
Interestingly, the prevalence, impairment and duration
of speciﬁc phobia were considerably higher in high-
and upper-middle-income countries than in low-/
lower-middle-income countries. This could be due to
cultural differences in the degree to which symptoms
of speciﬁc phobia are recognized or attributed to a
mental disorder and differences in catastrophic
cognitions about phobic/anxious symptoms (Hinton
& Pollack, 2009; Marques et al. 2011; Hofmann &
Hinton, 2014). Also, there could be differences in
how interview questions are interpreted, social
norms, attitudes and stigmas surrounding mental pro-
blems (Angermeyer & Dietrich, 2006; Lee et al. 2009).
For instance, differences in speciﬁc phobia duration
could be attributed to the reasons above but could
also reﬂect differences in the kinds and/or frequencies
of reported phobic stimuli. Although cross-national
differences could not be investigated in depth, the
results suggest that the phenomenology and under-
lying processes of speciﬁc phobia vary across coun-
tries. As observed previously (e.g. Stinson et al. 2007;
LeBeau et al. 2010), females showed higher speciﬁc
phobia prevalence than males.
Young age was also observed to be associated with
speciﬁc phobia, aligning with previous work (Stinson
et al. 2007; Sigström et al. 2016). Those with lower edu-
cation had higher odds of speciﬁc phobia, which has
been observed previously (Magee et al. 1996) but not
in all surveys (Stinson et al. 2007). Those with employ-
ment status ‘other’ (e.g. disabled, looking for a job)
showed higher odds of speciﬁc phobia. Magee et al.
(1996) found a similar association, but it has not been
investigated in other surveys.
Subtype-speciﬁc analyses showed that animal pho-
bia had the highest cross-national prevalence (3.8%;
1.4–8.1% across countries), in line with previous obser-
vations (3.3–7.0%; Curtis et al. 1998; Depla et al. 2008;
LeBeau et al. 2010). Fear of still water or weather events
had a prevalence of 2.3%, aligning with previously
reported prevalence rates for ‘water’ phobia (2.2–
3.4%) and ‘storm’ phobia (2.0–2.9%; LeBeau et al.
2010). For fear of heights, the cross-national prevalence
(2.8%) was somewhat lower than reported previously
(3.1–5.3%; LeBeau et al. 2010). The cross-national
prevalence of BIM phobia (3.0%) was in line with pre-
viously estimated prevalence rates (3.2–4.5%; LeBeau
et al. 2010). The cross-national prevalence rates fear of
closed spaces (2.2%) and fear of ﬂying (1.3%) were
both lower than reported previously (closed spaces:
3.2–3.3%; ﬂying: 2.5–2.9%; LeBeau et al. 2010). Apart
from methodological differences, some of the discrep-
ancies between current and previous ﬁndings could
be explained by variations across countries in culture
(see above) and rates of exposure (e.g. ﬂying is less
common in low-income countries). Investigation of
subtype co-occurrence showed that more than half of
patients had two or more lifetime fear subtypes and
that those with more subtypes had more severe clinical
characteristics (e.g. impairment, co-morbidity), align-
ing with previous results (e.g. Curtis et al. 1998).
The median AOO of speciﬁc phobia was found to be
young, showing relatively limited variation across sur-
veys (IQR = 5–13 years). In line with this, the projected
lifetime risk was only slightly higher than the observed
lifetime prevalence rates (range of absolute differences
across surveys: 0.1–1.2%; range of proportional differ-
ences across surveys: 1.7–22.0%). In line with previous
work (e.g. Burstein et al. 2012), the AOO distribution
showed some differences across subtypes, with more
early AOO for animal and natural phenomena pho-
bias. The observation of a younger AOO distribution
in those with multiple fear subtypes also aligns with
previous work (Burstein et al. 2012). Lifetime co-
morbidity levels in speciﬁc phobia were high (60.5%),
with some subtypes being associated with higher
levels than others. In the majority of co-morbid
cases, speciﬁc phobia onset preceded the other disor-
ders(s). In addition, co-morbidity became more com-
mon with increasing numbers of fear subtypes.
Together, these results support the idea that speciﬁc
phobia is an early-life indicator of psychopathology
vulnerability.
Severe role impairment was reported in roughly a
ﬁfth of 12-month speciﬁc phobia cases, but reported
impairment was lower in low-/lower-middle-income
countries than in the other countries. The mean num-
ber of days out of role in all subjects with 12-month
speciﬁc phobia was 12.2, but in respondents reporting
severe impairment, this number was much higher,
often in excess of a month, depending on the domain
of severe impairment. Twelve-month impairment
increased with the number of reported fear subtypes,
aligning with the idea that the presence of multiple
lifetime fears marks increased clinical severity.
Together, these results suggest that speciﬁc phobia
can have a severe impact on persons’ lives.
Treatment for speciﬁc phobia was threefold higher in
high-income countries than in low-/lower-middle-
income countries, which could be due to differences
in the availability of care and ﬁnancial resources
(Saxena et al. 2007; McBain et al. 2012), the perceived
need for treatment (Andrade et al. 2014), knowledge
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about mental healthcare (Palazzo et al. 2014) and preju-
dices (Clement et al. 2015; Semrau et al. 2015). Despite
differences in treatment rates, associations between the
level of impairment and percentages of reported treat-
ment were comparable across the income groups, with
severely impaired cases reporting most treatment.
These results indicate that self-reported impairment
could be an informative clinical speciﬁer indicating
need for care.
The current study had several limitations. First,
diagnoses were based on structured lay interviews.
However, a previous clinical reappraisal study (Haro
et al. 2006) showed sufﬁcient concordance between
CIDI-based and clinical diagnoses of speciﬁc phobia.
Second, all information about lifetime prevalence and
AOO was reported retrospectively. This could have
led to recall bias, which has been suggested to lead
to underestimated lifetime prevalence rates of common
mental disorders (Mofﬁtt et al. 2010). If this bias
affected reporting of speciﬁc phobia in the current
study, the true lifetime prevalence and co-morbidity
rates could be higher. Third, the included surveys dif-
fered in terms of their response rate and sampling
frames. Fourth, not all phobia types were systematic-
ally assessed (e.g. fear of choking, vomiting, contacting
an illness), which could have led to under-reporting.
Finally, the results are based on DSM-IV criteria for
speciﬁc phobia and using DSM-5 diagnoses could
have led to different results. Going from DSM-IV to
DSM-5, two important modiﬁcations were made to
the diagnostic criteria. First, persons above 18 years
are no longer required to recognize that their fear/
avoidance is excessive/unreasonable. Second, the fear/
avoidance should at least last 6 months in all persons.
Interestingly, the former modiﬁcation is likely to
increase prevalence, whereas the latter is likely to
decrease the prevalence, possibly counteracting each
other’s effects. Given the fact that the core features
have remained the same and the nature of the modiﬁ-
cations, strongly differing prevalence estimations
would not be expected.
Although cross-national differences were observed
in the prevalence, associated impairment and treat-
ment use, the results suggest that speciﬁc phobia is
associated with considerable impairment across the
world and often precedes other disorders. These
ﬁndings suggest that speciﬁc phobia deserves attention
of clinicians and researchers in view of its direct effects
on the global burden of disease, and its role in the
developmental unfolding of psychopathology.
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